

PRIOR AUTHORIZATION CRITERIA

BRAND NAME
(generic)

CEQUA
(cyclosporine ophthalmic solution)

RESTASIS
(cyclosporine ophthalmic emulsion)

Status: CVS Caremark Criteria

Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATION

Cequa

Cequa is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Restasis

Restasis is a topical immunomodulator indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for dry eye disease
AND
- The patient has experienced an inadequate treatment response to an artificial tears product
OR
- The patient has experienced an intolerance to an artificial tears product
OR
- The patient has a contraindication that would prohibit a trial of an artificial tears product

REFERENCES

1. Cequa [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; August 2018
2. Restasis [package insert]. Irvine, CA: Allergan, Inc; July 2017.
3. Restasis Multidose [package insert]. Irvine, CA: Allergan, Inc; October 2016.
4. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. <http://online.lexi.com/>. Accessed October 2019.
5. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. <http://www.micromedexsolutions.com/>. Accessed October 2019.
6. Preferred Practice Pattern. Dry Eye Syndrome. American Academy of Ophthalmology. November 2018.